Combination therapy with statins

Current Opinion in Investigational Drugs

Volumn 3, Issue 9, 2002, Pages 1318-1323

  Gylling, Helena ^b   Miettinen, Tatu A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cholesterol absorption; Cholesterol synthesis; Cholestyramine; Estrogen; Ezetimibe; Fibrates; LDL cholesterol; N 3 fatty acids; Niacin; Plant sterols; Serum triglycerides; Stanol ester; Statins

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; BEZAFIBRATE; BILE SALT; CERIVASTATIN; CHOLESTEROL; COLESTYRAMINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DOCOSAHEXAENOIC ACID; ESTROGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GUAR GUM; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEOMYCIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; POLYUNSATURATED FATTY ACID; PRAVASTATIN; PROGESTERONE; SIMVASTATIN; STANOL ESTER; UNINDEXED DRUG;

ABDOMINAL DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG STRUCTURE; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ILLNESS BEHAVIOR; LIVER TOXICITY; MALABSORPTION; MUSCLE DISEASE; MUSCLE INJURY; NONHUMAN; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

ANIMALS; DRUG THERAPY, COMBINATION; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHYTOSTEROLS;

EID: 0345270040     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kreisberg RA, Oberman A: Lipids and atherosclerosis: Lesson learned from randomised controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab (2002) 87:423-437.
2. Collins R, Peto R, Armitage J: The MRC/BHF Heart Protection Study: Preliminary results. Int J Clin Pract (2002) 56:53-56. The largest statin trial, which also delineates the lack of effect of antioxidant supplementation in coronary protection.
3. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: THe MIRACL study: A randomized controlled trial. J Am Med Assoc (2001) 285:1711-1718.
4. Miettinen TA: Cholesterol absorption inhibition: A strategy for cholesterol-lowering therapy. Int J Clin Pract (2001) 55:710-716.
5. Ros E: Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis (2000) 151:357-359.
6. Vuoristo M, Miettinen TA: Absorption and metabolism of cholesterol. In Fat Digestion and Absorption. Christophe AB, De Vriese S (Eds), AOCS Press, Champaign, IL, USA (2000):244-275.
7. Neil HA, Meijer GW, Roe LS: Randomized controlled trial of use by hypercholesterolaemic patients of avegetable oil sterol-enriched fat spread. Atherosclerosis (2001) 156:329-337.
8. Davidson MH, Maki KC, Umporowicz MS, Kate A, Ingram MPH, Diclin MR, Shaefer E, Lane RW, McNamara JR, Ribaya-Mercado JD, Perrone G et al: Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr (2001) 20:307-319.
9. Brink EJ, Hendriks HFJ: Long-term follow-up study on the use of a spread enriched with plant sterols. TNO Nutrition and Food Research Institute Report, V 99.869 March (2000).
10. Gylling H, Radhakrishnan R, Miettinen TA: Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malasorption induced by dietary sitostanol ester margarine: Women and dietary sitostanol. Circulation (1997) 96:4226-4231.
11. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol (2000) 86:46-52. Addition of plant stanol ester margarine to statin treatment for 8 weeks reduced LDL cholesterol by a further 10% in relation to statin-treated controls.
12. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA: Stanol ester margarine alone and with simvastatin lower serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol (2000) 20:500-506.
13. Gylling H, Miettinen TA: Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res (1996) 37:1776-1785. The metabolic and kinetic basis of stanol ester on serum cholesterol lowering is evaluated in detail.
14. Miettinen TA, Strandberg TE, Gylling H: Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: Relation to basal serum cholesterol. Artherioscler Thromb Vasc Biol (2000) 20:1340-1346. This study indicated for the first time that in coronary individuals with less favorable prognosis, levels of serum plant sterols and increased during long-term statin treatment.
15. Thompson GR, O'Neill F, Seed M: Why some patients respond poorly to statins and how this might be remedied. Eur Heart J (2002) 23:200-206. The concept that cholesterol metabolism regulates the response to statin treatment is discussed in detail.
16. Gylling H, Miettinen TA: Baseline intestinal absorption and synthesis of cholesterol regulates its response to hypolipidaemic treatments in coronary patients. Atherosclerosis (2002) 160:477-481.
17. Miettinen TA, Gylling H: ABCG5/8 genes responsible for serum plant sterol increase drug statin treatment. XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, NY, USA (2001):37.
18. Gylling H, Miettinen TA: Serum plant sterol levels on and off satin treatment and stanol vs sterol ester consumption in a homozygous form of familial hypercholesterolemia. XIV International Symposium on Drugs Affecting Lipids Metabolism, New York, NY, USA (2001):31.
19. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterowich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 290:1771-17775. This is the first report of a genetic defect in plant sterol absorption. The mechanism of cholesterol absorption (and of sterols in general) will be clarified after identifying the role of ABCG membrane proteins in the regulation of sterols in enterocytes and in biliary canaluculi.
20. Miettinen TA: Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: A case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur J Clin Invest (1980) 10:27-35.
21. Gylling H, Miettinen TA: LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterelemic coronary subjects. Nutr Metab Cardiovasc Dis (2002):in press.
22. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE Jr, Rajaratnam RA, Relas H: Inhibition of cholesterol synthesis and absorption in patients with acute myocardial infarction reduces serum cholesterol concentrations. (2002):manuscript submitted.
23. Gylling H, Miettinen TA: The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis (1995) 117:305-308.
24. Davis HR Jr, Compton DS, Hoos L, Tetzloff G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Artheroscler Thromb Vasc Biol (2001) 21:2032-2038.
25. Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW: The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxyl-methyl-glutarylcoenzyme A reductase inhibitor in dogs. Metabolism (2001) 50:1234-1241.
26. Davidson M, McQarry T, Bettis R, Melani L, Lipka L, BeBeaut A, Suresh R, Sun S, Veltri E, for the Ezetimibe Study Group: Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol (2002) 39 (Suppl 226A):1084-1090. This paper convincingly shows that the combination of ezetimibe with statins administered to large numbers of hypercholesterolemic patients further lowers LDL cholesterol by 12 to 14%, slightly lowers TG and increases HDL cholesterol by about 8%. In addition, a combination of ezetimibe with large doses of statins lowers LDL cholesterol by approximately 28% in homozygous FH patients.
27. Ballantyne C, Houri J, Notarbartolo A, Melani L, Lipka L, LeBeaut A, Suresh R, Sun S, Veltri E, for the Ezetimibe Study Group: Ezetimibe co-administratered with atorvastatin in 628 patients with primary cholesterol hypercholesterolemia. J Am Coll Cardiol (2002) 39(Suppl227A):1084-1091. This paper convincingly shows that the combination of ezetimibe with statins administered to large numbers of hypercholesterolemic patients further lowers LDL cholesterol by 12 to 14%, slightly lowers TG and increases HDL cholesterol by about 8%. In addition, a combination of ezetimbe with large doses of statins lowers LDL cholesterol by approximately 28% in homozygous FH patients.
28. Gagne C, Gaudet D, Bruckert E, Ponsonnet D, Lipka L, LeBeaut A, Suresh R, Abreu P, Veltri E, for the Ezetimibe Study Group: Ezetimibe significantly reduces low density lipoprotein cholesterol in homozygous familial hypercholesterolemia. J Am Coll Cardiol (2002) 39(Suppl 227A):1084-1092. This paper convicingly shows that the combination of ezetimibe with statins administered to large numbers of hypercholesterolemic patients further lowers LDL cholesterol by 12 to 14%, slightly lowers TG and increases HDL cholesterol by about 8%. In addition, a combination of ezetimibe with large doses of statins lowers LDL cholesterol by approximately 28% in homozygous FH patients.
29. Kosoglou T, Guillaume M, Sun S et al: Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis (2001) 2(Suppl):38.
30. Eriksson M, Hadell K, Holme I, Walldius G, Kjellström T: Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care. J Intern Med (1998) 243:373-380.
31. Uusitupa MI, Miettinen TA, Happonen P, Ebeling T, Turtola H, Voutilainen E, Pyörälä K: Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Artherioscler Thromb (1992) 12:807-813. This paper indicates that increases cholesterol synthesis by bile acid binding treatment (cholestyramine or guar gum) is at least partly inhibited when combined with statin treatment, resulting in marked overall reductions in total cholesterol concentrations.
32. White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB et al: Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation (2001) 104:2660-2665.
33. Athyros VG, Papageorgiou AA, Kontopoulos AG: Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolemia: A pilot study. Curr Med Res Opin (2001) 17:267-272.
34. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Linden T, Miettinen T, Odman B, Olofsson SO: Prasvastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med (1993) 94:13-20.
35. Vanhanen HT, Miettinen TA: Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis (1995) 115:135-146.
36. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M: Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis (2000) 150:429-436.
37. Shek A, Ferrill MJ: Statin-fibrate combination therapy. Ann Pharmacother (2001) 35:908-917.
38. Farmer JA: Learning from the cerivastatin experience. Lancet (2001) 358:1383-1385.
39. GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet (1999) 354:447-455.
40. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA: Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol (1997) 80:797-798.
41. Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC: Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Int Med (1998) 243:163-170.
42. Nordoy A, Hansen JB, Brox J, Svensson B: Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipidemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis (2001) 11:7-16.
43. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, France M: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart (2001) 85:544-548.
44. Darling GM, Johns JA, McCloud PI, Davis SR: Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. Climacteric (1999) 2:181-188.
45. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC: Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic postmenopausal women. Maturitas (2001) 40:247-257.
46. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, Cannon RO: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation (1999) 99:354-360.
47. Koh KK, Schenke WH, Waclawiw MA, Csako G, Cannon RO: Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation (2002) 105:1531-1533.
48. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol (1986) 8:1245-1255.
49. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 345:1583-1592.
50. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM: Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol (1998) 82:737-743.
51. Kashayap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO Jr, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 89:672-678.